No Data
MODERN CHI MED (01643): Xie Wanting has been appointed as co-company secretary.
MODERN CHI MED (01643) announced that Chen Zixin (formerly known as Chen Yanling) has submitted a resignation letter due to job changes, effective from...
MODERN CHI MED (01643.HK) expects annual net profit to be between 8 million and 12 million yuan.
On March 6, Glonghui reported that MODERN CHI MED (01643.HK) announced that the group expects to record a net profit of between 8 million yuan and 12 million yuan for the year ending December 31, 2024, while for the year ending December 31, 2023, it recorded a net profit of approximately 48.8 million yuan. The decrease in net profit is mainly attributed to: 1) the temporary cessation of production due to renovations in the preparation workshop from February to May 2024, along with a decrease in revenue caused by the new national policies and a reduction in the number of active clients; and 2) the removal of the preparation workshop resulting in property losses.
Express News | Modern Chinese Medicine Group Sees Decrease in FY Revenue
Express News | Modern Chinese Medicine - Expected Net Profit for 2024 Between RMB8.0 Mln and RMB12.0 Mln
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
